This implied that FH-EB02 primarily bound to tumor cells and blocked EGFR signaling through its interaction with B7H3, providing a large therapeutic window and thereby further reducing the binding of the bsAb to EGFR targets in normal tissues and mitigating side effects. The gene discussed is CD276; the disease is neoplasm.